AKT1 and small cell lung carcinoma: In conclusion, the present study revealed that apatinib inhibited SCLC tumour growth in vitro and in vivo by downregulating the expression of VEGF, pVEGFR2, p‐PI3K, p‐AKT, p‐ERK1/2, Ki‐67 and CD31.